Monday, December 23, 2024
HomeTagsTravere Therapeutics

Travere Therapeutics

Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA...

Ligand Pharmaceuticals Incorporated announced that its partner Travere Therapeutics, Inc.  has received accelerated approval from the U.S. Food and Drug Administration for FILSPARI to...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics